Replies to post #243895 on Biotech Values

[DewDiligence]

ADMP—(+42%/AH)—reverse-merges with_(private) DMK Pharmaceuticals:

https://www.globenewswire.com/news-release/2023/02/27/2616496/32832/en/Adamis-Pharmaceuticals-and-DMK-Pharmaceuticals-Announce-Agreement-and-Plan-of-Merger.html

DMK Pharmaceuticals, Corp. is a privately held, clinical stage neuro-biotechnology company focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved.

...Since the company’s inception, DMK’s development programs have been largely financed by non-dilutive funding from the government. DMK’s lead clinical stage product candidate, DPI-125, is being studied as a potential novel treatment for OUD. The company also plans to develop the compound for the treatment of moderate to severe pain, where it could potentially offer a superior safety profile with lower addiction risk than currently marketed opioids (pain killers) and hence help prevent opioid addiction. DMK’s other product candidates include DPI-221 being developed for treating bladder control problems and DPI-289 being developed for treating severe end stage Parkinson’s disease.

ADMP has effectively been a shell company since its COVID failure announced in Sep 2022 (#msg-170005508). The above PR does not give the approximate post-merger equity split, which is silly (IMO).

If you are suffering from insomnia, the merger agreement filed with the SEC might help:
https://www.sec.gov/Archives/edgar/data/887247/000183988223004983/ex2-1.htm